1. Home
  2. PRG vs TNDM Comparison

PRG vs TNDM Comparison

Compare PRG & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.75

Market Cap

1.4B

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$21.89

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
TNDM
Founded
2020
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PRG
TNDM
Price
$29.75
$21.89
Analyst Decision
Buy
Buy
Analyst Count
6
16
Target Price
$35.00
$22.44
AVG Volume (30 Days)
477.8K
2.3M
Earning Date
10-22-2025
11-06-2025
Dividend Yield
1.71%
N/A
EPS Growth
10.59
N/A
EPS
3.96
N/A
Revenue
$2,507,179,000.00
$1,007,001,000.00
Revenue This Year
$1.32
$8.59
Revenue Next Year
$0.64
$10.19
P/E Ratio
$7.67
N/A
Revenue Growth
3.71
17.87
52 Week Low
$23.50
$9.98
52 Week High
$48.77
$38.28

Technical Indicators

Market Signals
Indicator
PRG
TNDM
Relative Strength Index (RSI) 51.87 66.05
Support Level $28.88 $20.27
Resistance Level $31.52 $22.10
Average True Range (ATR) 1.02 1.12
MACD 0.22 -0.08
Stochastic Oscillator 56.21 91.59

Price Performance

Historical Comparison
PRG
TNDM

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: